JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB5475

Anti-VEGF Receptor 2 (phospho Y1214) 抗体

Anti-VEGF Receptor 2 (phospho Y1214) antibody

Be the first to review this product! Submit a review

|

(12 Publications)

Rabbit Polyclonal VEGF Receptor 2 phospho Y1214 antibody. Suitable for WB and reacts with Synthetic peptide - Human, Human samples. Cited in 12 publications.

別名を表示する

CD309, FLK1, VEGFR2, KDR, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, FLK-1

2 Images
Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (AB5475)
  • WB

Supplier Data

Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (AB5475)

Modulation of expression of target protein by cell treatment to demonstrate antibody specificity.

The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate

All lanes:

Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab5475) at 1/1000 dilution

Lane 1:

HT-29 (Human colorectal adenocarcinoma cell line) whole cell lysate at 30 µg

Lane 2:

HT-29 Serum Starved followed by treatment for 10 minutes with 100 ng/mL of SCF at 30 µg

Lane 3:

Caco-2 (Human colorectal adenocarcinoma cell line) whole cell lysate at 30 µg

Lane 4:

Caco-2 Serum Starved followed by treatment for 10 minutes with 100 ng/mL of SCF at 30 µg

Secondary

All lanes:

Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP conjugate at 1/5000 dilution

Predicted band size: 151 kDa

Observed band size: ~151 kDa

false

Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (AB5475)
  • WB

Unknown

Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (AB5475)

Peptide Competition and Stimulation : Extracts prepared from CSF-1 stimulated (1-4, 6) or unstimulated (5) PAE cells transfected with a chimeric CSF-1/VEGFR2 receptor were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C, then were incubated with 0.50 μg/mL ab5475 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with : no peptide (1, 5, 6), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphotyrosine containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5475 blocks the antibody signal, and the stimulation of the phospho signal after stimulating ligand is added (CSF-1 for the chimeric r

All lanes:

Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab5475)

Predicted band size: 151 kDa

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特異性

VEGFR3 has not been tested, but is expected to react.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.35-1 µg/mL", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Synthetic peptide - Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.35-1 µg/mL", "WB-species-notes": "<p></p>" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
精製に関する特記事項
The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated VEGFR 2 protein. The final product is generated by affinity chromatography using a VEGFR 2 derived peptide that is phosphorylated at Tyrosine 1214.
バッファー組成
pH: 7.3 Preservative: 0.05% Sodium azide Constituents: PBS, 0.1% BSA
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 2 also known as KDR or Flk-1 is a receptor tyrosine kinase important for mediating the effects of vascular endothelial growth factor (VEGF). This protein has a mass of approximately 150 kDa. It mostly expresses in vascular endothelial cells playing a primary role in the formation of blood vessels. The receptor can also be found in various non-endothelial tissues though in smaller amounts indicating its broad functional roles outside of the vascular system.
Biological function summary

VEGF Receptor 2 is important for angiogenesis and vascular permeability. It is part of the VEGF receptor family which also includes VEGF Receptors 1 and 3 forming a complex interaction network. Upon binding with VEGF it phosphorylates key proteins to initiate signals that regulate endothelial cell migration proliferation and survival. The receptor's function is critical for normal developmental processes and wound healing as well.

Pathways

VEGF Receptor 2 is especially important within the angiogenesis and vascular permeability pathways. It plays a central role in the VEGF signaling pathway alongside proteins like VEGF A which is the primary ligand for the receptor. The signaling through this receptor modulates various downstream proteins through phosphorylation linking it to pathways that control cellular responses essential for blood vessel formation and maintenance.

VEGF Receptor 2 is significantly linked with cancer and age-related macular degeneration. In the context of cancer the overexpression or dysregulation of VEGF and its receptors including VEGF Receptor 2 often leads to enhanced tumor angiogenesis promoting tumor growth and metastasis. Additionally the receptor interacts with other proteins in pathological states such as CD309 in endothelial cell-based assays which are used for research like flow cytometry and ELISA to monitor VEGF Receptor 2 activity and its impact on diseases.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
See full target information KDR phospho Y1214

文献 (12)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 15:5986 PubMed39013903

2024

Epidermal growth factor-like domain 7 drives brain lymphatic endothelial cell development through integrin αvβ3.

Applications

Unspecified application

Species

Unspecified reactive species

Jingying Chen,Jing Ding,Yongyu Li,Fujuan Feng,Yuhang Xu,Tao Wang,Jianbo He,Jing Cang,Lingfei Luo

Annals of translational medicine 9:1743 PubMed35071437

2022

Notoginsenoside R2 induces colonic microvascular injuries via regulating the Rap1GAP/PI3K/Akt signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Tao,Jiang Lin,Beiping Zhang,Shiying Wang

The Journal of biological chemistry 295:11466-11472 PubMed32518161

2020

Loss of the RNA-binding protein Rbm15 disrupts liver maturation in zebrafish.

Applications

Unspecified application

Species

Unspecified reactive species

Liang Hu,Hongyan Li,Zhiping Chi,Jianbo He

Cell death & disease 10:131 PubMed30755600

2019

P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoxiang Chen,Kaixuan Zeng,Mu Xu,Xiangxiang Liu,Xiuxiu Hu,Tao Xu,Bangshun He,Yuqin Pan,Huiling Sun,Shukui Wang

FASEB journal : official publication of the Federa 31:2001-2012 PubMed28183800

2017

TNFSF15 inhibits VEGF-stimulated vascular hyperpermeability by inducing VEGFR2 dephosphorylation.

Applications

Unspecified application

Species

Unspecified reactive species

Gui-Li Yang,Zilong Zhao,Ting-Ting Qin,Dong Wang,Lijuan Chen,Rong Xiang,Zhen Xi,Rongcai Jiang,Zhi-Song Zhang,Jianning Zhang,Lu-Yuan Li

Developmental biology 408:41-55 PubMed26455409

2015

The endocytic recycling regulatory protein EHD1 Is required for ocular lens development.

Applications

Unspecified application

Species

Unspecified reactive species

Priyanka Arya,Mark A Rainey,Sohinee Bhattacharyya,Bhopal C Mohapatra,Manju George,Murali R Kuracha,Matthew D Storck,Vimla Band,Venkatesh Govindarajan,Hamid Band

Journal of neuroinflammation 10:11 PubMed23339567

2013

Monocyte chemoattractant protein-1 affects migration of hippocampal neural progenitors following status epilepticus in rats.

Applications

IHC

Species

Unspecified reactive species

Yu-Wen Hung,Ming-Tsong Lai,Yi-Jhan Tseng,Chien-Chen Chou,Yung-Yang Lin

Developmental dynamics : an official publication o 241:684-96 PubMed22354878

2012

In vivo Notch reactivation in differentiating cochlear hair cells induces Sox2 and Prox1 expression but does not disrupt hair cell maturation.

Applications

Unspecified application

Species

Unspecified reactive species

Zhiyong Liu,Thomas Owen,Jie Fang,R Sathish Srinivasan,Jian Zuo

The Journal of clinical endocrinology and metaboli 96:E1973-81 PubMed21994955

2011

Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.

Applications

WB, IHC

Species

Human, Human

Anniina Färkkilä,Marjut Pihlajoki,Hanna Tauriala,Ralf Bützow,Arto Leminen,Leila Unkila-Kallio,Markku Heikinheimo,Mikko Anttonen

BMC developmental biology 10:13 PubMed20105280

2010

Activated Ras alters lens and corneal development through induction of distinct downstream targets.

Applications

IHC

Species

Unspecified reactive species

Daniel Burgess,Yan Zhang,Ed Siefker,Ryan Vaca,Murali R Kuracha,Lixing Reneker,Paul A Overbeek,Venkatesh Govindarajan
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com